Screen Design and Assay Technology Special Interest Group (SIG)

Wednesday, February 9, 2022

9:00 AM – 10:00 AM

Location: 252B

Kenda Evans, Ph.D.

Automation Product Specialist
Agilent Technologies, Texas, United States
Andrew Napper, PhD

Executive Director, Head of Automation and Assay Technologies
Bristol Myers Squibb, New Jersey, United States
Breanna Zerfas, PhD

Scientist II
Dana-Farber Cancer Institute‘s Center for Protein Degradation, Massachusetts, United States
Ellen Vieux, PhD

Senior Research Scientist I
C4 Therapeutics, Massachusetts, United States
Kristin M. Riching, PhD

Senior Scientist
Promega Corporation, Wisconsin, United States
Hannah Maple, PhD

Innovation Manager
Bio-Techne
Joe Baldick, PhD

Associate Director
Bristol Myers Squibb, New Jersey, United States

The Screen Design & Assay Technology SIG meets to share best practices and experience in the design of screens and deployment of assay technologies to advance drug discovery. Participation is encouraged from academic, biotech, pharma, and vendor communities.

For our meeting at SLAS 2022 we have assembled a panel of experts to discuss the following: "Targeted protein degradation—What are the most effective assay technologies and screening paradigms?" Each of the five panelists will present for 5-8 minutes, after which we will devote 20-30 minutes to Q&A and further discussion.

Please join us for a lively and topical meeting. For those unable to attend in person a recording will be available after 24 hours.